Jefferies
Jefferies provides research and execution services in equity, fixed income, and foreign exchange markets.
Business Model:
Revenue: $6B
Employees: 5,001-10,000
Rankings
Industries / Tags:
Detailed Jefferies Information
Jefferies was acquired by
Jefferies Financial Group.
The acquisition happend on 2012-11-12.
Details of the transaction were not public
Acquirer
Geographic Data
Address: 520 Madison Ave
City: New York
State: NY
Zip: 10022
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Facebook
Twitter
Linkedin
Crunchbase
Metrics
332,919Website Global Rank
173,184Website Monthly Traffic
Twitter Followers
Description
Jefferies provides research and execution services in equity, fixed income, and foreign exchange markets. Jefferies, a major global securities and investment banking group, has served companies and their investors for nearly 50 years and operates in more than 25 cities around the world. They provide world-class investment banking, sales and trading, research and asset management to a diverse range of corporate clients, institutional investors and high net worth individuals. They are industry experts, specializing in aerospace and defense, consumer energy, financial services, gaming and leisure, healthcare, industrials, maritime, media, real estate &a; lodging, technology, and telecommunications, with a dedicated private equity coverage group.
Contact Phone:
+12122842300
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 8/2014 | Avant | Debt Financing | 200M |
| 1/2000 | Enterworks Acquisition Inc. | Venture Round | 25M |
| 9/2019 | Petal | Debt | 300M |
| 4/2018 | CloudMargin | Venture Round | 10M |
| 3/2000 | 1800wedding.com | Series C | 10.4M |
| 6/2021 | Entrinsic Bioscience | Debt Financing | 49M |
| 1/2018 | Visible Alpha | Venture Round | 38M |
| 10/2018 | Petal | Debt Financing | 34M |
| 10/2018 | Ualá | Series B | 0 |
| 6/2014 | Ablynx | Post-IPO Equity | 0 |
| 10/2017 | Abeona Therapeutics | Post-IPO Equity | 0 |
| 8/2016 | Advaxis | Post-IPO Equity | 0 |
| 7/2022 | Illuminate Financial | Venture Round | - |
| 5/2019 | Figure | Debt Financing | 0 |
| 3/2016 | Liminal BioSciences | Post-IPO Debt | 30M |
| 10/2014 | Symphony Communication Services | Series A | 66M |
| 2/2022 | Superpedestrian | Series C | 0 |
| 3/2022 | NextRNA Therapeutics | Series A | 0 |
| 7/2014 | Aura Financial | Series B | 0 |
| 3/2011 | BONDS.COM | Venture Round | 0 |
| 1/2019 | dv01 | Series B | 15M |
| 2/2017 | Bond Street | Debt Financing | 300M |
| 3/2000 | THINQ Learning Solutions | Series C | 0 |
| 6/2016 | dv01 | Convertible Note | 5M |
| 1/2017 | Ualá | Seed Round | - |
| 4/2016 | Affirm | Series D | 100M |
| 4/2015 | Avant | Debt Financing | 400M |
| 9/2017 | Ualá | Convertible Note | - |
| 2/2022 | Superpedestrian | Debt Financing | - |
| 2/2018 | Ualá | Series A | 10M |
| 5/2015 | Affirm | Series B | 275M |
| 6/2015 | Bond Street | Series A | 10M |
| 6/2015 | Bond Street | Debt Financing | 100M |
| 7/2022 | Illuminate Financial | Venture Round | - |
| 3/2022 | NextRNA Therapeutics | Series A | 0 |
| 2/2022 | Superpedestrian | Debt Financing | - |
| 2/2022 | Superpedestrian | Series C | 0 |
| 6/2021 | Entrinsic Bioscience | Debt Financing | 0 |
| 9/2019 | Petal | Debt Financing | 0 |
| 5/2019 | Figure | Debt Financing | 0 |
| 1/2019 | dv01 | Series B | 0 |
| 10/2018 | Ualá | Series B | 0 |
| 10/2018 | Petal | Debt Financing | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
